A5065917399- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Nonmelanoma Skin Cancer Studies
- Ocular Oncology and Treatments
- Immune Cell Function and Interaction
- Immune cells in cancer
- Full-Duplex Wireless Communications
- Polyomavirus and related diseases
- Psoriasis: Treatment and Pathogenesis
- melanin and skin pigmentation
- Dermatologic Treatments and Research
- Brain Metastases and Treatment
- Cell Image Analysis Techniques
- Cancer and Skin Lesions
- Computational Drug Discovery Methods
- Tumors and Oncological Cases
- vaccines and immunoinformatics approaches
- Biosimilars and Bioanalytical Methods
- Cell Adhesion Molecules Research
- Antenna Design and Analysis
- Protein Degradation and Inhibitors
- Ear and Head Tumors
Université Côte d'Azur
2021-2024
Centre Hospitalier Universitaire de Nice
2020-2024
Observatoire de la Côte d’Azur
2024
Centre Méditerranéen de Médecine Moléculaire
2024
Inserm
2024
Hôpital l'Archet
2018-2022
There is no standard of care for unresectable cutaneous squamous cell carcinoma (cSCC). Chemotherapy, alone or combined with radiotherapy, commonly used mostly as palliative treatment; moreover, its poor safety profile limits use most the time, especially in elderly patients. Thus, alternative options are needed. Targeted molecular inhibitors, such epidermal growth factor receptor inhibitor cetuximab, seem promising, but data limited. We retrospectively evaluated clinical outcomes cetuximab...
Background Despite significant progress with antiprogrammed cell death protein 1 (PD-1) therapy, a substantial fraction of metastatic melanoma patients show upfront therapy resistance. Biomarkers for outcome are missing and the association baseline immune function clinical remains to be determined. We assessed in vitro nonspecific stimulation response at during anti-PD-1 melanoma. Methods Previously untreated received nivolumab radiotherapy as part multicentric phase II trial NIRVANA (...
Testing for the BRAF mutation is mandatory management of patients with locally advanced or metastatic melanoma. Molecular analysis based on DNA sequencing remains gold-standard method screening different mutations. These methods must be rapid, sensitive, and specific enough to allow optimal therapeutic in daily practice also include clinical trials. Here, we compared Idylla Mutation Test anti-BRAF V600E (clone VE1) immunohistochemistry (IHC) 90 melanoma samples, a focus challenging cohort 32...
This case report describes a 78-year old woman with stage IIA BRAF wild-type melanoma on the left leg who experienced grade 2 vitiligo, marked skin thickening, and painful swelling of limbs.
Despite the undeniable progress made with new therapies, notably targeted therapies (TT), and immunotherapies (Luke et al., 2017Luke J.J. Flaherty K.T. Ribas A. Long G.V. Targeted agents immunotherapies: optimizing outcomes in melanoma.Nat Rev Clin Oncol. 2017; 14: 463-482Crossref PubMed Scopus (898) Google Scholar), prognosis of metastatic cutaneous melanoma remains poor. In patients BRAFV600 mutation, TT using BRAF inhibitors, now combination MEK inhibitors show dramatic results terms...
The outcome of patients with cutaneous melanoma has been strongly modified by recent advances obtained Immune Checkpoint Inhibitors (ICIs). However, despite this breakthrough, durable response to ICIs is limited a subset patients. We investigated whether the expression TRF2, which preserves telomere integrity, and have an effect on tumor immunosurveillance notably directly recruiting activating myeloid-derived suppressor cells (MDSCs), could be prognostic biomarker in relapsed or metastatic...
An amendment to this paper has been published and can be accessed via the original article.
Abstract Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer, associated with high mortality. Immune checkpoint inhibitors (ICIs) have demonstrated long‐lasting efficiency for treating advanced MCC. Despite good safety profile, ICI remain non‐negligible risk of immune‐related adverse events (irAEs), which may require treatment discontinuation if they are severe. We report the case complete response to Avelumab after rechallenge in patient metastatic MCC who became...
Abstract Background Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine malignancy. Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with metastatic MCC (mMCC). In mMCC, response duration after cessation of ICIs complete (CR) unknown. Observation We report case woman in her 70s treated first‐line avelumab. The was stopped 2 years CR. patient relapsed 11 months rechallenge avelumab at same dosing regimen decided. first tumour...